Deldeprevir (sodium)

Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C^[1][2][3]. In Vitro:Deldeprevir sodium (3 days; antiviral combination study) exhibits higher in vitro potency against genotype-1a and 1b HCV replicons than BMS-032, and its combination with ACH-3102 reduces the emergence of resistance variants in these replicon cell lines^[1].
ACH-2684 (Deldeprevir sodium) (3 days) exhibits higher in vitro potency against genotype 1a and 1b HCV replicons than a reference NS3 protease inhibitor, and displays additive or synergistic antiviral efficacy when combined with a HCV NS5A inhibitor while reducing resistance variant emergence^[2].
Combining Deldeprevir sodium with the NS5B nucleotide inhibitor ACH-3422, or with ACH-3422 plus the NS5A inhibitor ACH-3102, enhances antiviral activity and blocks the emergence of ACH-3422-resistant HCV replicons in vitro^[3].